(Desert Hot Springs, California, USA) – Royal Emerald Pharmaceuticals (REP) is poised to receive the first-of-its-kind federal (DEA) license to research, develop and manufacture medicines derived from THC and CBD . Royal Emerald’s mission is to be leaders in the pharmaceutical field by creating non-addictive medicines for veterans, law enforcement and first responders suffering from ailments, such as, PTSD, pain, anxiety, depression, sleep apnea, opiate addiction and other ailments. “Our veterans and first responders have paid a tremendous price sacrificing for the betterment of our communities .

Source: First of its Kind Pharmaceutical Company Awaits U.S. Federal License to Develop Medicines Derived from THC and CBD